Innerworld@lemmy.worldM to Litigation Settlements@lemmy.worldEnglish · 5 days agoAmgen Inc.'s ChemoCentryx Inc. will pay $69 million to settle investor class allegations that it overhyped the safety of its drug to treat severe vasculitisnews.bloomberglaw.comexternal-linkmessage-square0linkfedilinkarrow-up14arrow-down10
arrow-up14arrow-down1external-linkAmgen Inc.'s ChemoCentryx Inc. will pay $69 million to settle investor class allegations that it overhyped the safety of its drug to treat severe vasculitisnews.bloomberglaw.comInnerworld@lemmy.worldM to Litigation Settlements@lemmy.worldEnglish · 5 days agomessage-square0linkfedilink
